Technology ID
TAB-3701
HeLa Cells Stably Expressing YFP-Parkin and mt-mKeima to Study Parkinson Disease
E-Numbers
E-093-2018-0
Lead Inventor
Youle, Richard (National Institute of Neurological Disorders and Stroke)
Co-Inventors
Wang, Chunxin (Black) (National Institute of Neurological Disorders and Stroke)
Applications
Software / Apps
Research Materials
Non-Medical Devices
Medical Devices
Diagnostics
Therapeutic Areas
Neurology
Lead IC
NINDS
This technology includes a cell line that stably expresses YFP-Parkin and mt-mKeima that can be used to study mitochondrial degradation, mitophagy, using flow cytometry (FACS). Compromised mitophagy is implicated in Parkinson disease. The effects of any compounds or genetic alteration on Parkin-mediated mitophagy can be monitored.
Commercial Applications
This cell line could be useful for testing potential drugs' effect on Parkin-mediated mitophagy using flow cytometry (FACS).
Competitive Advantages
There is a similar technique to monitor mitophagy with mito-QC (mCherry-GFP-Fis1) but it is not commercialized. Mitophagy can be examined using Western, however, this method is tedious, less sensitive and can be affected by many human errors during the Western blot process. In contrast, the mt-mKeima based mitophagy assay is more robust, consistent, objective, and quantitative.
Licensing Contact: